CA
NZ
UK
AU
IND
US
The company operates with reported debt of $8.91 million against $9.61 million in cash and equivalents. These figures indicate a relatively stableLiquidityposition. However, Rockwell faces significant challenges as it continues to report declining revenues alongside negative net margins, drawing attention from investors who closely …
LENSAR, Inc. achieved notable success in its second quarter of 2026, reporting an 18% increase in revenue compared to previous periods. This growth was largely driven by a remarkable 23% rise in procedure revenue, indicating heightened utilization of its ALLY laser cataract surgery system. …
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC), a medical technology firm specializing in solutions for neurological disorders, achieved a significant revenue milestone of $2 million in Q3 2026, marking a 16% year-over-year increase from $1.7 million in the prior year. This growth underscores the company's …
Pelthos Therapeutics Inc. (NYSE American: PTHS) is a biopharmaceutical firm focused on innovative therapeutic products targeting unmet patient needs, especially in dermatological conditions. As it reports its financial results for the second quarter of 2026, Pelthos achieved an astounding 3100% revenue surge, elevating quarterly …
Recent discussions around prescription drug pricing highlight a growing concern: many consumers are facing costs that exceed their monthly mortgage payments. This troubling trend has brought to light the underlying issues in the current pharmaceutical pricing model, where companies often base drug costs on …
SS Innovations International, Inc. (NASDAQ: SSII), a key player in medical specialties, reported a notable surge in revenue for the second quarter of 2026, boosting figures by 39.4% to $13.9 million. This increase comes on the heels of a steady rise in demand for …
Collegium Pharmaceutical, Inc. (NASDAQ: COLL), a notable player in the pharmaceuticals sector with a marketCapitalizationof approximately $837 million, has taken a decisive step to enhance shareholder value by executing a $50 million accelerated share repurchase agreement with Jefferies LLC. This announcement follows the company’s …
Fate Therapeutics, Inc. (NASDAQ: FATE), a pioneering clinical-stage biopharmaceutical company focused on cellular immunotherapy, reported second-quarter revenue of $6.32 million, marking a 52.6% year-over-year decline. This drop reflects the ongoing challenges within the biotechnology sector as the company navigates through developmental hurdles, including regulatory …
LENSAR, Inc. (NASDAQ: LNSR) recorded a remarkable $16.5 million in revenue for the second quarter ended June 30, 2026, reflecting an 18% year-over-year growth from $13.9 million in the same quarter last year. This improvement underscores the increasing utilization of its ALLY Robotic Cataract …
MiNK Therapeutics, Inc. (NASDAQ: INKT) operates in the biotechnology sector, focusing on innovative treatments for cancer and immune disorders. The company reported a marketCapitalizationof about $56 million and $9.53 million in cash and equivalents. This financial position supports its efforts to develop its lead …
Please wait processing your request...